Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFINE-MS ocrelizumab dosing interval trial in relapsing-remitting multiple sclerosis
ISRCTN17105865Phase 3Recruiting
- Sponsor
- University College London
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) (5 arms), sponsored by University College London. Primary endpoints: Proportion of participants without new T2 lesions at 1 year and Proportion of participants without new T2 lesions at 2 years. Started May 2026; status: recruiting.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on ISRCTN17105865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17105865.